These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 10933051

  • 21. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity.
    Toda M, Rabkin SD, Kojima H, Martuza RL.
    Hum Gene Ther; 1999 Feb 10; 10(3):385-93. PubMed ID: 10048391
    [Abstract] [Full Text] [Related]

  • 22. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207.
    Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T.
    Jpn J Cancer Res; 2000 Dec 10; 91(12):1339-44. PubMed ID: 11123435
    [Abstract] [Full Text] [Related]

  • 23. Head and neck squamous cell carcinoma targeted chemosensitization.
    Figures MR, Wobb J, Araki K, Liu T, Xu L, Zhu H, O'Malley BW, Li D.
    Otolaryngol Head Neck Surg; 2009 Aug 10; 141(2):177-83. PubMed ID: 19643248
    [Abstract] [Full Text] [Related]

  • 24. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.
    Mashour GA, Moulding HD, Chahlavi A, Khan GA, Rabkin SD, Martuza RL, Driever PH, Kurtz A.
    Exp Neurol; 2001 May 10; 169(1):64-71. PubMed ID: 11312559
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer.
    Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H, Fong Y.
    Cancer Gene Ther; 2002 Nov 10; 9(11):935-45. PubMed ID: 12386832
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Therapeutic effect of adenovirus-mediated transfer of the wild-type p53 gene with cisplatin].
    Fujiwara T, Ogawa N, Kagawa S, Nishizaki M, Yasuda T, Tanaka N, Orita K, Roth JA.
    Gan To Kagaku Ryoho; 1996 Jul 10; 23(8):1085-8. PubMed ID: 8687228
    [No Abstract] [Full Text] [Related]

  • 31. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.
    Blank SV, Rubin SC, Coukos G, Amin KM, Albelda SM, Molnar-Kimber KL.
    Hum Gene Ther; 2002 Mar 20; 13(5):627-39. PubMed ID: 11916486
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
    Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T.
    Clin Cancer Res; 2005 Nov 01; 11(21):7886-90. PubMed ID: 16278413
    [Abstract] [Full Text] [Related]

  • 36. S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.
    Kaliyaperumal K, Sharma AK, McDonald DG, Dhindsa JS, Yount C, Singh AK, Won JS, Singh I.
    Redox Biol; 2015 Dec 01; 6():41-50. PubMed ID: 26177470
    [Abstract] [Full Text] [Related]

  • 37. Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12.
    Iizuka Y, Suzuki A, Kawakami Y, Toda M.
    J Immunother; 2004 Dec 01; 27(2):92-8. PubMed ID: 14770080
    [Abstract] [Full Text] [Related]

  • 38. Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma.
    Goh AR, Shin SP, Jung NR, Ryu CH, Eom HS, Lee JH, Choi K, Lee SJ, Jung YS.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):743-50. PubMed ID: 25449436
    [Abstract] [Full Text] [Related]

  • 39. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk.
    Morris JC, Wildner O.
    Mol Ther; 2000 Jan 28; 1(1):56-62. PubMed ID: 10933912
    [Abstract] [Full Text] [Related]

  • 40. Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma.
    Pin RH, Reinblatt M, Fong Y.
    Ann Surg; 2004 Oct 28; 240(4):659-65; discussion 665-6. PubMed ID: 15383793
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.